First-line treatment of advanced breast cancer with sunitinib in combination with docetaxel versus docetaxel alone: Results of a prospective, randomized phase III study

Bergh, J.; Bondarenko, I.; Lichinitser, M.; Liljegren, A.; Greil, R.; Voytko, N.; Makhson, A.; Cortes, J.; Lortholary, A.; Bischoff, J.; Chan, Arlene; Delaloge, S.; Huang, X.; Kern, K.; Giorgetti, C.

Access Status

Fulltext not available

Authors

Bergh, J.

Bondarenko, I.

Lichinitser, M.

Liljegren, A.

Greil, R.

Voytko, N.

Makhson, A.

Cortes, J.

Lortholary, A.

Bischoff, J.

Chan, Arlene

Delaloge, S.

Huang, X.

Kern, K.

Giorgetti, C.

Date

2012

Type

Journal Article

Metadata

Show full item record

Citation

Bergh, J. and Bondarenko, I. and Lichinitser, M. and Liljegren, A. and Greil, R. and Voytko, N. and Makhson, A. et al. 2012. First-line treatment of advanced breast cancer with sunitinib in combination with docetaxel versus docetaxel alone: Results of a prospective, randomized phase III study. Journal of Clinical Oncology. 30 (9): pp. 921-929.

Source Title

Journal of Clinical Oncology